Obesity is costing the world billions of pounds every year

What is so novel and exciting about Acomplia is that it functions completely differently to the other weight loss drugs Reductil and Xenical.  Reductil is also an appetite suppressant but it does not function in the same way as Acomplia. Acomplia actually works on brain receptors which control the desire to eat. Acomplia is made by the French drug firm Sanofi-Aventis.

Another major drug company a few years back namely Merck decided to develop a similar medication that would work on brain receptors to control appetite in the same way and have been busy with a phase 3 clinical trial. The new diet drug is called taranabant and the gossip that we have heard at Ukmedix News shows that the results have been extremely good.

Almost two and a half thousand men and women have been testing the drug over the last 24 months and on the strength of the clinical results it is expected that Merck will file a proper application for approval of the new medicine to the Food & Drug Administration sometime in the second quarter of 2008. As with common practice very little info has been released by the drug company Merck about the results of the trials however from tit bits of information coming from the participants of the clinical trials it appears that things are moving well.

Great scientific advances have been made in medications over the last few years that specifically work on brain receptors and drug companies are heavily investing in this sort of research. It is reckoned that over the next few decades the world will see many many more drugs on the market to cure a whole list of ailments from a neurological angle as opposed to a physical point of view.

Weight loss drugs are in great demand all over the world as so many developed countries are experiencing great rises in the number of obese citizens. Obesity is costing the world billions of pounds every year in medical bills and thus the financial returns on weight loss drugs have great potential.